The first and only oral proteasome inhibitor
NINLARO® (ixazomib) - Multiple Myeloma Treatment
The approval of the NINLARO® (ixazomib) regimen (NINLARO+lenalidomide+dexamethasone) was based on a statistically significant ~6 month improvement in median progression-free survival vs the placebo regimen (placebo+lenalidomide+dexamethasone) (median: 20.6 vs 14.7 months [95% CI, 17.0-NE and 95% CI, 12.9-17.6, respectively]; HR=0.74 [95% CI, 0.587-0.939]; P=0.012).